Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · October 26, 2016

Lack of Cost-Effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

JAMA: The Journal of the American Medical Association

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA: The Journal of the American Medical Association
Cost-Effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
JAMA 2016 Aug 16;316(7)743-753, DS Kazi, AE Moran, PG Coxson, J Penko, DA Ollendorf, SD Pearson, JA Tice, D Guzman, K Bibbins-Domingo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading